相似文献
1
What are the challenges faced by COVID-19 vaccines?
Expert Rev Vaccines. 2022 Jan;21(1):5-7. doi: 10.1080/14760584.2022.2008245. Epub 2021 Nov 26.
2
Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of Adenovirus Vector-Based COVID-19 Vaccines?
Pain Med. 2021 Jun 4;22(6):1441-1464. doi: 10.1093/pm/pnab130.
3
[What are the differences between the various covid-19 vaccines?].
Ned Tijdschr Tandheelkd. 2021 Jul 6;128(epub ahead of print 2021). doi: 10.5177/ntvt.2021.epub.21038.
4
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
Front Immunol. 2021 Oct 11;12:714170. doi: 10.3389/fimmu.2021.714170. eCollection 2021.
5
Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.
J Korean Med Sci. 2021 Apr 19;36(15):e110. doi: 10.3346/jkms.2021.36.e110.
6
Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?
Int J Infect Dis. 2021 Sep;110:258-260. doi: 10.1016/j.ijid.2021.06.040. Epub 2021 Jun 23.
7
The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines.
J Pharm Sci. 2021 Feb;110(2):627-634. doi: 10.1016/j.xphs.2020.11.015. Epub 2020 Nov 23.
8
Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines.
Ann Neurol. 2021 Nov;90(5):856-858. doi: 10.1002/ana.26218. Epub 2021 Sep 28.
9
Joining forces to administer COVID-19 vaccines.
J Osteopath Med. 2021 Mar 5;121(4):429-430. doi: 10.1515/jom-2021-0034.
10
Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
Front Immunol. 2021 Nov 23;12:779453. doi: 10.3389/fimmu.2021.779453. eCollection 2021.
引用本文的文献
1
Dissociable impacts of physical and psychological factors on side effects after COVID-19 vaccination in Japan: A within-subject repeated measures design.
BMC Psychol. 2025 Sep 1;13(1):995. doi: 10.1186/s40359-025-03325-4.
2
mRNA Vaccination for COVID-19 Lowers the Risk for Pulmonary Fibrosis Through GIP-10/Gal-3/HIF-1 Downregulation.
Cureus. 2025 May 17;17(5):e84269. doi: 10.7759/cureus.84269. eCollection 2025 May.
3
Quantifying the Adverse Effects of Long COVID on Individuals' Health After Infection: A Propensity Score Matching Design Study.
Risk Manag Healthc Policy. 2024 Mar 24;17:701-713. doi: 10.2147/RMHP.S446321. eCollection 2024.
4
Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.
Biomed Res Int. 2023 May 4;2023:4588659. doi: 10.1155/2023/4588659. eCollection 2023.
5
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.
Comput Biol Med. 2022 Sep;148:105814. doi: 10.1016/j.compbiomed.2022.105814. Epub 2022 Jul 11.
6
Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.
Immunotargets Ther. 2022 May 18;11:23-35. doi: 10.2147/ITT.S360151. eCollection 2022.
7
Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.
Int J Gen Med. 2022 Mar 3;15:2415-2425. doi: 10.2147/IJGM.S356547. eCollection 2022.
Zotero 插件